Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Bob L who wrote (6683)	5/20/1999 8:30:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 9719

Bob: Thanks again. However, in this instance, I think that you finally missed the mark......... Avicidan isn't targeted to lymphoma, and the NSC antibody certainly can't be considered to be "commercially available". Here's the statement from the release............ ''Proof that this concept works has now been demonstrated in lymphoma patients with a commercially available antibody,'' said Dr. Abrams................... NeoRx is currently in the process of developing its own lead antibody to bring to the clinic for this indication. But, I'll bet you're correct. I'll bet that they're doing the lymphoma MAb (anti-CD20?????) with NSC. Cheers! Rick